<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00200746</url>
  </required_header>
  <id_info>
    <org_study_id>R21AT002394-01A1</org_study_id>
    <nct_id>NCT00200746</nct_id>
  </id_info>
  <brief_title>Treatment of Alcohol-Related Hepatitis With Arginine</brief_title>
  <official_title>Arginine Treatment for Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Complementary and Integrative Health (NCCIH)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of the amino acid arginine in reducing&#xD;
      liver injury in individuals with alcohol-related hepatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arginine is a naturally occurring amino acid that is also available in pill form. Arginine&#xD;
      pills have been shown to aid in liver detoxification and fat breakdown in the liver. Numerous&#xD;
      studies have examined the effects of arginine on the liver. However, few have determined the&#xD;
      optimal concentration of arginine that would best prevent injury to the liver This study will&#xD;
      provide participants with three concentration levels of arginine to determine which is most&#xD;
      effective in reducing liver injury in alcoholic hepatitis patients.&#xD;
&#xD;
      This study will last 31 days. Participants will be admitted to the General Clinical Research&#xD;
      Center for 27 days. Participants will be randomly assigned to one of four groups.&#xD;
      Participants in Groups 1, 2, and 3 will have 1%, 2%, or 6% arginine added to their diet in&#xD;
      the form of gel capsules. Participants in Group 4 will receive placebo capsules. Participants&#xD;
      will be given 24 capsules of different dietary supplements, including the arginine&#xD;
      supplements, every day during their hospital stay.&#xD;
&#xD;
      Participants who are not able to ingest at least 18 capsules per day over 3 days or who are&#xD;
      not able to eat the majority of their solid or liquid diet while hospitalized will have a&#xD;
      naso-gastric soft feeding tube inserted for food and supplements to be administered. A liver&#xD;
      biopsy will be performed on Days 3 and 26. The biopsies will involve insertion of a catheter&#xD;
      in a neck vein and a small sample of liver tissue will be removed. On Days 2 and 25,&#xD;
      participants will undergo blood and urine collection. Participants will also be infused with&#xD;
      nonradioactive leucine to determine the levels of albumin, a protein that is reduced in&#xD;
      diseased livers. If participants develop fluid in the abdomen (a condition known as ascites),&#xD;
      a small sample of fluid will be extracted from the abdomen twice a day on Days 2, 17, and 25.&#xD;
      On Day 31, participants will return to the research center for additional blood and urine&#xD;
      collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of enrollment&#xD;
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in liver endotoxin production</measure>
    <time_frame>After nutritional intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in Maddrey's discriminant function (DF) score</measure>
    <time_frame>After nutritional intervention</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate Arginine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Polycose control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Arginine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine</intervention_name>
    <description>Amino Acid Arginine</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of alcoholic hepatitis&#xD;
&#xD;
          -  Maddrey's DF score less than 33&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatitis C or B virus infected&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Hepatic encephalopathy (a condition in which liver failure affects the central nervous&#xD;
             system)&#xD;
&#xD;
          -  Kidney failure&#xD;
&#xD;
          -  A Do Not Resuscitate order (a patient-directed order not to resuscitate in the event&#xD;
             that resuscitation is necessary to prevent death)&#xD;
&#xD;
          -  Maddrey's DF score of 33 or greater after vitamin K administration during the study&#xD;
&#xD;
          -  Alcohol withdrawal at study entry&#xD;
&#xD;
          -  Active pneumonia at study entry&#xD;
&#xD;
          -  Allergy to iodine&#xD;
&#xD;
          -  Enrollment in any other clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A. Tayek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Biomedical Research Institute at Harbor - University of Los Angeles Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor - University of California Los Angeles Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <name_title>John Tayek, M.D.</name_title>
    <organization>La BioMedical</organization>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Arginine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

